Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain-Reference-Cited by-同舟云学术

Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain

Published:2004-12 Issue:8 Volume:28 Page:1287-1297
ISSN:0278-5846
Container-title:Progress in Neuro-Psychopharmacology and Biological Psychiatry
language:en
Short-container-title:Progress in Neuro-Psychopharmacology and Biological Psychiatry

Author:

Bobes Julio,Cañas Fernando,Rejas Javier,Mackell Joan

Publisher

Elsevier BV

Subject

Biological Psychiatry,Pharmacology

Reference51 articles.

1. Bodyweight gain induced by Psychotropic Drugs. Incidence, mechanisms and management;Ackerman;CNS Drugs,1998

2. Antipsychotic-induced weight gain: a comprehensive research synthesis;Allison;Am. J. Psychiatry,1999

3. Symptoms, signs and diagnosis of schizophrenia;Andreasen;Lancet,1995

4. An overview of adverse reactions caused by typical antipsychotics;Arana;J. Clin. Psychiatry,2000

5. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol;Beasley;Br. J. Psychiatry,1999

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation;AAPS PharmSciTech;2020-04

2. Optimization and in vitro evaluation of ziprasidone nanosuspensions produced by a top-down approach;Journal of Drug Delivery Science and Technology;2019-08

3. Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis;Expert Review of Pharmacoeconomics & Outcomes Research;2019-06-20

4. Systematic review of pharmacoeconomic models for schizophrenia;Journal of Market Access & Health Policy;2018-01

5. Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders;Acta Pharmaceutica;2017-02-21